Original Articles

Progesterone Challenge Test in Screening of Endometrial Pathologic Lesions in High-Risk Post-Menopausal Women

Abstract

Objective: This study aimed to evaluate the prognostic value of the progesterone challenge test (PCT) in the diagnosis of hyperplastic and cancerous endometrium in high-risk postmenopausal women.
Materials and methods: In this cross-sectional study, 72 postmenopausal women without abnormal uterine bleeding who had risk factors for endometrial cancer were recruited. Patients with endometrial thickness of 4 mm or more as determined transvaginal ultrasonography were tested with progesterone challenge test. If there were any bleeding (spotting to severe bleeding) in the next two weeks, the test would be considered positive. After two weeks, all of the participants despite the result of PCT underwent office endometrial biopsy. In the end, all the results of PCT were compared with endometrial biopsy results.
Results: The mean age of the participants was 57.7 ±8.15 years. The progesterone challenge test
was positive in 17 women (22%).  Among the participants with positive progesterone challenge test, most of them show hyperplasia (62.5%) and 4.2% show endometrial cancer. According to the results, PCT had 37.5% accuracy, 20.8% sensitivity, 70.8 % specificity, 58.8% positive predictive value (PPV), and 30.9 % negative predictive value (NPV) for diagnosis of endometrial pathology.
Conclusion: We suggest that due to the unacceptable sensitivity and specificity of the PCT, this test alone is not suitable for screening of endometrial cancer or hyperplasia.

1. Lu KH, Broaddus RRJNEJoM. Endometrial cancer. N Engl J Med. 2020;383(21):2053-64.
2. Tzenios N, Chahine M, Tazanios M. Obesity and endometrial cancer: the role insulin resistance and adipokines. Special journal of the Medical Academy and other Life Sciences. 2023;1(2).
3. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S,
Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008;17(4):921-9.
4. Esmaeilzadeh A, Akhavan Rezayat K, Masannen Mozaffari H, Bahari A, Ghanaei O, Ganji A, et al. Prevalence of hereditary nonpolyposis colorectal cancer in patients with colorectal cancer in Iran: a systematic review. Reviews in Clinical Medicine. 2016;3(3):98-104.
5. Rezaianzadeh A, Dehghani SL, Mousavi M, Rezaeianzadeh R. The incidence of uterus cancer in Iran: a systematic review. Women’s Health Bulletin. 2017;4(1):1-4.
6. Costas L, Frias‐Gomez J, Guardiola M, Benavente Y, Pineda M, Pavón MÁ, et al. New perspectives on screening and early detection of endometrial cancer. International journal of cancer. 2019;145(12):3194-206.
7. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491-505.
8. Clarke MA, Long BJ, Morillo ADM, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA internal medicine. 2018;178(9):1210-22.
9. Yasa C, Dural O, Bastu E, Ugurlucan FG, Nehir A, İyibozkurt AC. Evaluation of the diagnostic role of transvaginal ultrasound measurements of endometrial thickness to detect endometrial malignancy in asymptomatic postmenopausal women. Archives of gynecology and obstetrics. 2016;294:311-6.
10. Gentry-Maharaj A, Karpinskyj C. Current and future approaches to screening for endometrial cancer. Best practice & research Clinical obstetrics & gynaecology. 2020;65:79-97.
11. Macia M, Novo A, Ces J, Gonzalez M, Quintana S, Codesido J. Progesterone challenge test for the assessment of endometrial pathology in asymptomatic menopausal women. International Journal of Gynecology & Obstetrics. 1993;40(2):145-9.
12. El-Maraghy M, El-Badawy N, Wafa G, Bishai NJM. Progesterone challenge test in postmenopausal women at high risk. Maturitas. 1994;19(1):53-7.
13. Rani PR, Devi JK, Papa D, Jayanthi S. Transvaginal
sonography and progesterone challenge test for identifying endometrial pathology in postmenopausal women. J Obstet Gynaecol India. 2002;52:135-8.
14. Toppozada M, Ismail A, Hamed R, Ahmed KS,
El-Faras A. Progesterone challenge test and estrogen assays in menopausal women with endometrial adenomatous hyperplasia. International Journal of Gynecology & Obstetrics. 1988;26(1):115-9.
15. GAMBRELL Jr RD, MASSEY FM, CASTANEDA TA, UGENAS AJ, RICCI CA, WRIGHT JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstetrics & Gynecology. 1980;55(6):732-8.
16. Gambrell Jr RJCio, gynaecology. The role of hormones in the etiology and prevention of endometrial cancer. Clin Obstet Gynaecol. 1986;13(4):695-723.
17. Toppozada M, Ismail A, Hamed R, Ahmed KS, El-Faras AJIJoG, Obstetrics. Progesterone challenge test and estrogen assays in menopausal women with endometrial adenomatous hyperplasia. 1988;26(1):115-9.
18. KWACK M-J, JOO S-H, KIM K-H, PARK C-H, PARK J-WJKJoO, Gynecology. Correlation of Progesterone Challenge Test and Endometrial Thickness in Postmenopausal Women. 2005:575-80.
19. Chu HJUiM, Biology. 3272: The value of progesterone challenge test combined with transvaginal ultrasonography detect endometrial diseases in postmenopausal asymptomatic women. 2006;32(5):P235.
20. Ivanov S, Karag'ozov A, Kŭrlov T, Ts D, Gancheva A, Chakalova GJAiG. The early detection and screening of endometrial carcinoma by the progesterone test and uterine sonography. Akush Ginekol (Sofiia). 1993;32(2):24-5.
21. López DML, Fernandez YG, Rodríguez BR, López FMO, Delgado RCJM. Value of the progesterone test in screening for endometrial pathology in asymptomatic postmenopausal women receiving treatment with tamoxifen. Menopause. 2010;17(3):487-93.
Files
IssueVol 19, No 2 (June 2025) QRcode
SectionOriginal Articles
DOI https://doi.org/10.18502/jfrh.v19i2.19298
Keywords
Progesterone Challenge Test Endometrial Hyperplasia Endometrial Cancer
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Tehranian A, Alambeygi H, Abbasi S, Ghahghaei-Nezamabadi A, Ghaemi M, Karimi R. Progesterone Challenge Test in Screening of Endometrial Pathologic Lesions in High-Risk Post-Menopausal Women. J Family Reprod Health. 2025;19(2):106-110.